HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens
Author
dc.contributor.author
Ferrer Campos, Pablo
Author
dc.contributor.author
Rodríguez, Consuelo
Author
dc.contributor.author
Sciaraffia Rubio, Alicia
Author
dc.contributor.author
Tordecilla Fernández, Rocío Pilar
Author
dc.contributor.author
Ramos, Verónica
Author
dc.contributor.author
Durán, Magdalena
Author
dc.contributor.author
Beltrán, Carlos
Author
dc.contributor.author
Afani Saud, Alejandro
Admission date
dc.date.accessioned
2021-03-31T20:51:26Z
Available date
dc.date.available
2021-03-31T20:51:26Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
Journal of Virus Eradication 6 (2020) 100002
es_ES
Identifier
dc.identifier.other
10.1016/j.jve.2020.06.002
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/178898
Abstract
dc.description.abstract
In this viewpoint we would like to describe our results in terms of resistance pattern in Chilean patients with virological failure (VF) on raltegravir (RAL)-containing-regimens and highlight the need for the concomitant availability of genotypic resistance testing to integrase strand transfer inhibitors (INSTIs) introduction in anti-retroviral regimens, particularly in countries in South America. Indeed we found in our study the presence of two or more primary mutations in some of the participants which is associated with cross-resistance to all INSTIs. By using timely genotyping, we could optimally manage these patients, early after detection of VF.
es_ES
Patrocinador
dc.description.sponsorship
OAIC, University of Chile Clinical Hospital
OAIC 560/13